A Phase 1 interventional study of Pregabalin 100mg and Acetaminophen 1300mg in Postoperative Pain, sponsored by Nevakar, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-05.
Sponsored by Nevakar, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.
Among the 65 studies testing pregabalin in Pain, Postoperative, this one is the 49th largest by enrollment, is one of 5 that started in 2020, is one of 5 in phase 1, and was the 46th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →7 of the 65 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Tanta University · Sites in Egypt
Ages 21–60
Bahrain Defence Force Hospital · Sites in Bahrain
Ages 18–85
Medical University of Warsaw · Sites in Poland
Ages 18+
Ain Shams University · Sites in Egypt
Ages 21–45 · Women only · Healthy volunteers
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 20 · Phase 4 21
First in 2005; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 65 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 65 have an industry lead sponsor. The 10 most frequent:
Nevakar, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Nevakar, Inc. has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
3 of the studies testing pregabalin in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05150795Ain Shams UniversityEffect of Preoperative Oral Pregabalin Versus Intraoperative Fentanyl on Postoperative Analgesia | 2026-12 |
| NCT07344467Tanta UniversityOral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing pregabalin in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine a maximum tolerated dose of IV PGB and to evaluate the safety, tolerability, and PK of an admixture of IV PGB and a fixed dose of 1300 mg IV APAP in healthy adult volunteers.
This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine a maximum tolerated dose (MTD) of IV PGB and to evaluate the safety, tolerability, and PK of an admixture of IV PGB and a fixed dose of 1300 mg IV APAP in healthy adult volunteers.
Up to 60 subjects will be enrolled into one (1) of six (6) sequential cohorts (n=10 per cohort [8 APAP + PGB and 2 placebo]).
The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg) based on Safety Monitoring Committee decision.
The placebo will be the saline solution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).
Drug: Pregabalin 100mg · Drug: Acetaminophen 1300mg
Saline solution
Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.
Drug: Pregabalin 100mg · Drug: Acetaminophen 1300mg
Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
Also known as: PGB
Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Also known as: Ofirmev
Treatment Related Adverse Events
The incidence and severity of treatment-emergent adverse events
Time frame: 7 days
Treatment related Drowsiness and Dizziness
The incidence and severity of somnolence and dizziness
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, Cmax
Maximum observed concentration
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, Tmax
Time to maximum observed drug concentration (Tmax)
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, t1/2
Apparent elimination half-life
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, AUC0-last
Area under the drug concentration-time curve from time zero to the last measurable concentration
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, AUC0-inf
AUC from time zero to infinity
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, λz
Apparent terminal elimination rate constant
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, CL
Apparent clearance
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, SAD Phase, Vz
Apparent terminal volume of distribution
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, AUCτ
Area under the plasma concentration-time curve during a dosage interval
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Tmax,ss
Time to Cmax at SS
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Cmax,ss
Maximum concentration at SS
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Cmin,ss
Minimum concentration at ss
Time frame: 7 dyas
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Cav,ss
Average plasma concentration at SS
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Vz, ss
Apparent volume of distribution at SS
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, CLss
Apparent total clearance at SS
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, λz,ss
Apparent first order terminal elimination rate constant at steady state
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, R
Accumulation index
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state, LF
Linearity factor
Time frame: 7 days
Plasma PK endpoints for APAP and PGB, multiple doses at steady state
Fluctuation ratio
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Jun 2020, 5 months.
Of 83 phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Acetaminophen
Nevakar, Inc.